close icon
Powrót do bloga

Will Moderna Strike a Deal with The US Government to Fund New Bird Flu Vaccines?

June 2, 2024

In the wake of the increased bird flu, mRNA vaccine pioneer Moderna is entering the final stages of their testing against this virus. The US government is now expected to fund this development. After the pandemic, pharmaceutical companies producing vaccines and medicines must make up for the weaking demand by developing new products that not only help the world fight dangerous diseases but can also bring profits for them.

Will Moderna Strike a Deal with The US Government to Fund New Bird Flu Vaccines?

Agreement on bird flu vaccines imminent

The Financial Times has published a report on an emerging agreement between Moderna and the US government to fund the final trials of a new vaccine against the bird flu virus, which has begun to dangerously spread among cattle and poultry in the US and could also affect humans. Funding, which could begin as early as next month, is to be provided by the Biomedical Advanced Research and Development Agency (BARDA), an institution under the US Department of Health and Human Services. The agreement includes potential grants worth tens of millions of dollars, as well as the purchase of vaccines in the event of successful tests, as stocks of existing vaccines would be insufficient in the event of a pandemic outbreak. Moderna is known for its breakthrough mRNA vaccines, which can be quickly modified and adapted to changing viral threats. This allows a potential epidemic or pandemic to be managed effectively. In addition to Moderna, Pfizer is also in talks with the US government about funding for bird flu vaccines, but specific information is not yet available in this matter.

After a second confirmed human case of bird flu virus was reported in early April, Moderna's shares began to rise after several months of decline, and their price has already risen by more than 40% since then. It is now at its highest level since February last year. *

Snímek obrazovky 2024-06-03 v 16.28.49

Source: Investing.com*

Moderna surprised with its financial results

At the beginning of May, Moderna published its economic results for the first quarter of 2024, which turned out to be a positive surprise despite the negative profit numbers. The loss per share was only $3.07, while the expected figure was $3.58. Total revenue was US$167 million, beating initial estimates of US$97.5 million. Moderna posted a net loss of $1.18 billion. Due to effective cost-cutting measures and surprisingly strong sales of Covid-19 vaccines, the company saw smaller losses. These vaccines are currently its only available product on the market, and vaccination demand has declined significantly after the pandemic.  Moderna is awaiting US approval of its new respiratory RSV vaccine, which was due on 12th of May, but the US Food and Drug Administration (FDA) has delayed that decision until the end of May.

Covid vaccines still in play

Although the Covid-19 pandemic has passed, the virus is not gone, and new vaccines are still in development. In particular, the pharmaceutical company Novavax is preparing to offer its vaccines against the new variant in the United States as early as this fall. While mRNA vaccines produced by Moderna, Pfizer or BioNTech can be launched in a short time, Novavax produces traditional protein-based variants that take months to produce. Company, like its competitors, has been losing value since the end of the pandemic. A new $1.2 billion licensing deal with Sanofi could improve its situation.

Snímek obrazovky 2024-06-03 v 16.28.54

Source: Investing.com*

Conclusion

Moderna's agreement with the U.S. government to fund final stage trials of a new mRNA vaccine against bird flu could bring it tens of millions of dollars, new source of revenue and strengthen its market position. Despite the decline in demand for Covid-19 vaccines, as pharmaceutical companies move forward with their vaccine and drug development, they compete in reaction speed to new potential health threats.

Warning! This marketing material is not and must not be understood as investment advice. Data relating to the past are not a guarantee of future returns. Investing in foreign currency may affect returns due to fluctuations. All securities transactions can lead to both profits and losses. Forward-looking statements represent assumptions and current expectations that may not be accurate or are based on the current economic environment, which may change. These statements are not guarantees of future performance. InvestingFox is a trademark of CAPITAL MARKETS, o.c.p., a.s. regulated by the National Bank of Slovakia.

* Data relating to the past are not a guarantee of future returns.

Sources:

https://www.investing.com/news/stock-market-news/us-nears-deal-to-fund-modernas-bird-flu-vaccine-trial-ft-reports-3462406

https://www.cnbc.com/2024/05/02/moderna-mrna-earnings-q1-2024.html

https://www.empr.com/home/news/drugs-in-the-pipeline/fda-decision-on-modernas-mrna-based-rsv-vaccine-delayed/

https://www.investing.com/news/stock-market-news/novavax-awaits-fda-decision-on-whether-its-next-covid-shot-can-be-offered-in-us-3457007

InvestingFox jest znakiem towarowym spółki CAPITAL MARKETS, o.c.p., a.s. z siedzibą przy ulicy Slávičie údolie 106, Bratysława – dzielnica Staré Mesto 811 02. Spółka jest wpisana do Rejestru Handlowego Sądu Miejskiego Bratysława III, sekcja: Sa, numer wpisu: 4295/B, numer identyfikacyjny: 36 853 054, numer identyfikacji podatkowej: 2022505419.

CAPITAL MARKETS, o.c.p., a.s. jest podmiotem prowadzącym działalność w zakresie obrotu papierami wartościowymi zgodnie z § 55 ust. 1 ustawy nr 566/2001 Z. z. o papierach wartościowych i usługach inwestycyjnych oraz o zmianie i uzupełnieniu niektórych ustaw w brzmieniu późniejszych przepisów (zwanej dalej ustawą o papierach wartościowych). Spółce CAPITAL MARKETS, o.c.p., a.s. w dniu 30.10.2007 r. przyznano decyzją Narodowego Banku Słowacji nr OPK-2297/2007 -PLP zezwolenie na świadczenie usług inwestycyjnych w rozumieniu § 54 ust. 2 w związku z § 59 ust. 2 i 3 ustawy o papierach wartościowych, które zgodnie z przepisami ustawy o papierach wartościowych zostało rozszerzone decyzją nr OPK-1830/2008-PLP z dnia 21 kwietnia 2008 r., decyzją nr OPK-11601-1/2008 z dnia 28 stycznia 2009 r., decyzją nr ODT-5059-3/2012 z dnia 23 lipca 2012 r. oraz decyzją nr ODT-9332/2014-1 z dnia 21 października 2014 r.

Czytaj więcej

Otrzymuj najważniejsze wiadomości na swój e-mail
SK hynix Reports 632% Increase in Operating Profit: AI Memory Generates Nearly 80% Margin

SK hynix Reports 632% Increase in Operating Profit: AI Memory Generates Nearly 80% Margin

On October 28, SK hynix released results showing the significant growth in profitability among suppliers of memory for artificial intelligence. Operating profit was more than seven times last year’s level and exceeded analysts’ expectations. The company also unveiled a full-year plan to return approximately $75 billion in capital to shareholders. For investors, the key question now is whether the company can maintain these high profits as it continues to expand production. [1]

SpaceX: Revenue Up 161% and in Talks About a Possible Merger with Tesla

SpaceX: Revenue Up 161% and in Talks About a Possible Merger with Tesla

On October 20, SpaceX released results showing a fundamental transformation of its business. Strong revenue growth from artificial intelligence helped the company achieve its first profitable quarter since going public. Elon Musk also confirmed discussions regarding a potential merger with Tesla. Investors were thus presented with strong results as well as a new strategic question that could reshape both companies. SpaceX shares rose by approximately 8% in after-hours trading.* [1]

JPMorgan Chase rozczarowuje Wall Street: nawet zysk w wysokości 15,3 mld dolarów okazał się niższy od oczekiwań

JPMorgan Chase rozczarowuje Wall Street: nawet zysk w wysokości 15,3 mld dolarów okazał się niższy od oczekiwań

13 października JPMorgan Chase opublikował wyniki za trzeci kwartał 2026 r., które okazały się nieoczekiwanym rozczarowaniem dla Wall Street. Największy bank w USA odnotował zysk w wysokości 5,57 USD na akcję, podczas gdy prognozy wynosiły 5,85 USD, a według danych LSEG po raz pierwszy od czwartego kwartału 2023 r. nie udało mu się osiągnąć prognozowanych wyników finansowych. Niższe przychody z rynków obligacji oraz spowolnienie w bankowości inwestycyjnej uwypukliły obszary, w których wzrost banku napotyka ograniczenia. Dla inwestorów kluczowym pytaniem jest teraz, czy bank będzie w stanie utrzymać wzrost przychodów, jednocześnie radząc sobie z rosnącymi kosztami.1

Kontrakty CFD to złożone instrumenty i wiążą się z wysokim ryzykiem szybkiej utraty pieniędzy z powodu dźwigni finansowej. 84.35% rachunków inwestorów detalicznych traci pieniądze podczas handlu CFD. Należy rozważyć, czy rozumie się, jak działają kontrakty CFD i czy można sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy.